Financing

Pro-Pharmaceuticals Closes Financing

Published in Healthcare Mergers, Acquisitions and Ventures Week, March 15th, 2008

Pro-Pharmaceuticals, Inc. (Amex: PRW), reported it has closed its previously announced registered direct equity offering of common stock and warrants. The Company received net proceeds of approximately $3.5 million.

"This financing, together with the 'friends and family' private placement we recently completed, enables us to reach critical milestones for DAVANAT(R) and our fibrosis compounds," said Theodore Zucconi, Ph.D., President, Pro-Pharmaceuticals, Inc.

Keywords: Financing, Pharmaceutical Business, Pharmaceutical Company, Pro-Pharmaceuticals Inc., Pro-Pharmaceuticals Inc.

This article was prepared by Healthcare Mergers,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week

Source: Healthcare Mergers, Acquisitions and Ventures Week (2008-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry